Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
Sponsor: United Immunity, co., Ltd.
Summary
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
Official title: A Phase I/II Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7/8 Agonist in Patients With Selected Locally Advanced and/or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-05-25
Completion Date
2031-03-31
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
UI-102
Specified dose on specified days
Locations (3)
NEXT Oncology
Dallas, Texas, United States
NEXT Oncology
Houston, Texas, United States
Next Oncology
San Antonio, Texas, United States